Revolution Medicines Inc
NASDAQ:RVMD
Balance Sheet
Balance Sheet Decomposition
Revolution Medicines Inc
Revolution Medicines Inc
Balance Sheet
Revolution Medicines Inc
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
9
|
70
|
17
|
104
|
109
|
161
|
696
|
543
|
384
|
|
| Cash Equivalents |
9
|
70
|
17
|
104
|
109
|
161
|
696
|
543
|
384
|
|
| Short-Term Investments |
0
|
0
|
106
|
337
|
469
|
484
|
1 157
|
1 746
|
1 642
|
|
| Total Receivables |
0
|
7
|
9
|
6
|
6
|
5
|
1
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
6
|
5
|
1
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
9
|
3
|
7
|
7
|
11
|
25
|
38
|
49
|
|
| Total Current Assets |
9
|
85
|
134
|
454
|
590
|
660
|
1 879
|
2 328
|
2 075
|
|
| PP&E Net |
5
|
7
|
7
|
36
|
71
|
74
|
100
|
142
|
165
|
|
| PP&E Gross |
5
|
7
|
7
|
36
|
71
|
74
|
100
|
142
|
165
|
|
| Accumulated Depreciation |
2
|
4
|
6
|
8
|
11
|
15
|
18
|
22
|
29
|
|
| Intangible Assets |
0
|
63
|
62
|
61
|
60
|
59
|
58
|
57
|
56
|
|
| Goodwill |
0
|
15
|
15
|
15
|
15
|
15
|
15
|
15
|
15
|
|
| Other Long-Term Assets |
0
|
1
|
3
|
1
|
3
|
5
|
10
|
18
|
44
|
|
| Other Assets |
0
|
15
|
15
|
15
|
15
|
15
|
15
|
15
|
15
|
|
| Total Assets |
15
N/A
|
171
+1 030%
|
221
+29%
|
567
+157%
|
738
+30%
|
812
+10%
|
2 062
+154%
|
2 558
+24%
|
2 355
-8%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
3
|
5
|
11
|
13
|
14
|
21
|
62
|
54
|
65
|
|
| Accrued Liabilities |
3
|
7
|
13
|
22
|
34
|
36
|
78
|
109
|
218
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
18
|
19
|
12
|
13
|
5
|
4
|
1
|
8
|
|
| Total Current Liabilities |
8
|
31
|
43
|
47
|
60
|
62
|
144
|
164
|
290
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
268
|
|
| Deferred Income Tax |
0
|
12
|
8
|
7
|
7
|
7
|
3
|
2
|
2
|
|
| Other Liabilities |
3
|
31
|
17
|
38
|
68
|
58
|
89
|
127
|
162
|
|
| Total Liabilities |
11
N/A
|
74
+604%
|
68
-8%
|
93
+36%
|
135
+46%
|
127
-6%
|
236
+86%
|
293
+24%
|
723
+147%
|
|
| Equity | ||||||||||
| Common Stock |
72
|
205
|
305
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
68
|
110
|
157
|
266
|
453
|
701
|
1 138
|
1 738
|
2 869
|
|
| Additional Paid In Capital |
0
|
1
|
5
|
740
|
1 056
|
1 388
|
2 963
|
4 002
|
4 497
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
2
|
1
|
1
|
3
|
|
| Total Equity |
5
N/A
|
97
+2 049%
|
153
+58%
|
475
+211%
|
603
+27%
|
685
+14%
|
1 826
+167%
|
2 265
+24%
|
1 631
-28%
|
|
| Total Liabilities & Equity |
15
N/A
|
171
+1 030%
|
221
+29%
|
567
+157%
|
738
+30%
|
812
+10%
|
2 062
+154%
|
2 558
+24%
|
2 355
-8%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
53
|
53
|
59
|
67
|
74
|
91
|
165
|
186
|
197
|
|